U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H32O3
Molecular Weight 344.4885
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEDROXYPROGESTERONE

SMILES

C[C@@]1([H])C[C@]2([H])[C@]([H])(CC[C@@]3(C)[C@@]2([H])CC[C@@]3(C(=O)C)O)[C@@]4(C)CCC(=O)C=C14

InChI

InChIKey=FRQMUZJSZHZSGN-HBNHAYAOSA-N
InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1

HIDE SMILES / InChI
Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. Medroxyprogesterone acetate (MPA) administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered MPA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROVERA

Approved Use

Medroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets.

Launch Date

-3.32639994E11
Primary
PROVERA

Approved Use

Medroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets.

Launch Date

-3.32639994E11
Preventing
PROVERA

Approved Use

Medroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets.

Launch Date

-3.32639994E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.71 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEDROXYPROGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.01 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEDROXYPROGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.6 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEDROXYPROGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEDROXYPROGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
150 mg 3 times / month multiple, intramuscular
Recommended
Dose: 150 mg, 3 times / month
Route: intramuscular
Route: multiple
Dose: 150 mg, 3 times / month
Sources: Page: p.7
healthy, 15 - 51
n = 3900
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 15 - 51
Sex: F
Population Size: 3900
Sources: Page: p.7
Disc. AE: Bleeding, Amenorrhea...
AEs leading to
discontinuation/dose reduction:
Bleeding (8.2%)
Amenorrhea (2.1%)
Weight gain (2%)
Sources: Page: p.7
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
E2V, p.o(2 mg; q.d)
Sources: Page: p.12
healthy, 45-66
n = 132
Health Status: healthy
Condition: Postmenopause
Age Group: 45-66
Sex: F
Population Size: 132
Sources: Page: p.12
Disc. AE: Bleeding, Uterine fibroids...
AEs leading to
discontinuation/dose reduction:
Bleeding (3.8%)
Uterine fibroids (2.3%)
Gallstones (0.76%)
Endometrial polyp (0.76%)
Sources: Page: p.12
2.5 mg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1325
healthy, 45-79
n = 284
Health Status: healthy
Condition: Postmenopause
Age Group: 45-79
Sex: F
Population Size: 284
Sources: Page: p.1325
Disc. AE: Bleeding vaginal...
AEs leading to
discontinuation/dose reduction:
Bleeding vaginal (9%)
Sources: Page: p.1325
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, 50 -79
n = 8506
Health Status: healthy
Condition: Postmenopause
Age Group: 50 -79
Sex: F
Population Size: 8506
Sources: Page: p.1, p.5
Disc. AE: Myocardial infarction, Stroke...
AEs leading to
discontinuation/dose reduction:
Myocardial infarction
Stroke
Breast cancer invasive NOS
Embolism pulmonary
Deep vein thrombosis
Sources: Page: p.1, p.5
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.628
unhealthy, >18
n = 83
Health Status: unhealthy
Condition: Idiopathic heavy menstrual bleeding
Age Group: >18
Sex: F
Population Size: 83
Sources: Page: p.628
Disc. AE: Dizziness, Fluid retention...
AEs leading to
discontinuation/dose reduction:
Dizziness (1.2%)
Fluid retention (1.2%)
Sources: Page: p.628
2.5 mg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, >65
Health Status: healthy
Condition: Postmenopause
Age Group: >65
Sex: F
Sources: Page: p.1, p.5
Disc. AE: Dementia...
AEs leading to
discontinuation/dose reduction:
Dementia
Sources: Page: p.1, p.5
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Secondary Amenorrhea|Abnormal Uterine Bleeding Due to Hormonal Imbalance
Sex: F
Sources: Page: p.1
Disc. AE: Cardiovascular disorder...
AEs leading to
discontinuation/dose reduction:
Cardiovascular disorder
Sources: Page: p.1
150 mg 3 times / month multiple, intramuscular
Recommended
Dose: 150 mg, 3 times / month
Route: intramuscular
Route: multiple
Dose: 150 mg, 3 times / month
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Prevention of pregnancy
Sex: F
Sources: Page: p.1
Disc. AE: Bone density abnormal...
AEs leading to
discontinuation/dose reduction:
Bone density abnormal
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Weight gain 2%
Disc. AE
150 mg 3 times / month multiple, intramuscular
Recommended
Dose: 150 mg, 3 times / month
Route: intramuscular
Route: multiple
Dose: 150 mg, 3 times / month
Sources: Page: p.7
healthy, 15 - 51
n = 3900
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 15 - 51
Sex: F
Population Size: 3900
Sources: Page: p.7
Amenorrhea 2.1%
Disc. AE
150 mg 3 times / month multiple, intramuscular
Recommended
Dose: 150 mg, 3 times / month
Route: intramuscular
Route: multiple
Dose: 150 mg, 3 times / month
Sources: Page: p.7
healthy, 15 - 51
n = 3900
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 15 - 51
Sex: F
Population Size: 3900
Sources: Page: p.7
Bleeding 8.2%
Disc. AE
150 mg 3 times / month multiple, intramuscular
Recommended
Dose: 150 mg, 3 times / month
Route: intramuscular
Route: multiple
Dose: 150 mg, 3 times / month
Sources: Page: p.7
healthy, 15 - 51
n = 3900
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 15 - 51
Sex: F
Population Size: 3900
Sources: Page: p.7
Endometrial polyp 0.76%
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
E2V, p.o(2 mg; q.d)
Sources: Page: p.12
healthy, 45-66
n = 132
Health Status: healthy
Condition: Postmenopause
Age Group: 45-66
Sex: F
Population Size: 132
Sources: Page: p.12
Gallstones 0.76%
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
E2V, p.o(2 mg; q.d)
Sources: Page: p.12
healthy, 45-66
n = 132
Health Status: healthy
Condition: Postmenopause
Age Group: 45-66
Sex: F
Population Size: 132
Sources: Page: p.12
Uterine fibroids 2.3%
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
E2V, p.o(2 mg; q.d)
Sources: Page: p.12
healthy, 45-66
n = 132
Health Status: healthy
Condition: Postmenopause
Age Group: 45-66
Sex: F
Population Size: 132
Sources: Page: p.12
Bleeding 3.8%
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
E2V, p.o(2 mg; q.d)
Sources: Page: p.12
healthy, 45-66
n = 132
Health Status: healthy
Condition: Postmenopause
Age Group: 45-66
Sex: F
Population Size: 132
Sources: Page: p.12
Bleeding vaginal 9%
Disc. AE
2.5 mg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1325
healthy, 45-79
n = 284
Health Status: healthy
Condition: Postmenopause
Age Group: 45-79
Sex: F
Population Size: 284
Sources: Page: p.1325
Breast cancer invasive NOS Disc. AE
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, 50 -79
n = 8506
Health Status: healthy
Condition: Postmenopause
Age Group: 50 -79
Sex: F
Population Size: 8506
Sources: Page: p.1, p.5
Deep vein thrombosis Disc. AE
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, 50 -79
n = 8506
Health Status: healthy
Condition: Postmenopause
Age Group: 50 -79
Sex: F
Population Size: 8506
Sources: Page: p.1, p.5
Embolism pulmonary Disc. AE
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, 50 -79
n = 8506
Health Status: healthy
Condition: Postmenopause
Age Group: 50 -79
Sex: F
Population Size: 8506
Sources: Page: p.1, p.5
Myocardial infarction Disc. AE
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, 50 -79
n = 8506
Health Status: healthy
Condition: Postmenopause
Age Group: 50 -79
Sex: F
Population Size: 8506
Sources: Page: p.1, p.5
Stroke Disc. AE
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, 50 -79
n = 8506
Health Status: healthy
Condition: Postmenopause
Age Group: 50 -79
Sex: F
Population Size: 8506
Sources: Page: p.1, p.5
Dizziness 1.2%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.628
unhealthy, >18
n = 83
Health Status: unhealthy
Condition: Idiopathic heavy menstrual bleeding
Age Group: >18
Sex: F
Population Size: 83
Sources: Page: p.628
Fluid retention 1.2%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.628
unhealthy, >18
n = 83
Health Status: unhealthy
Condition: Idiopathic heavy menstrual bleeding
Age Group: >18
Sex: F
Population Size: 83
Sources: Page: p.628
Dementia Disc. AE
2.5 mg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Co-administed with::
conjugated estrogens, p.o(0.625 mg; q.d)
Sources: Page: p.1, p.5
healthy, >65
Health Status: healthy
Condition: Postmenopause
Age Group: >65
Sex: F
Sources: Page: p.1, p.5
Cardiovascular disorder Disc. AE
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Secondary Amenorrhea|Abnormal Uterine Bleeding Due to Hormonal Imbalance
Sex: F
Sources: Page: p.1
Bone density abnormal Disc. AE
150 mg 3 times / month multiple, intramuscular
Recommended
Dose: 150 mg, 3 times / month
Route: intramuscular
Route: multiple
Dose: 150 mg, 3 times / month
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Prevention of pregnancy
Sex: F
Sources: Page: p.1
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
yes
likely (co-administration study)
Comment: Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of contraceptive drug products.
PubMed

PubMed

TitleDatePubMed
Organ preserving method in the management of atypical endometrial hyperplasia.
2001
Vascularization pattern of C6 glioma is modified with medroxyprogesterone acetate and ibuprofen in Wistar rat brain.
2001
Quantitative determination of medroxyprogesterone acetate in plasma by liquid chromatography/electrospray ion trap mass spectrometry.
2001
[A case of pulmonary lymphangioleiomyomatosis originally treated as bronchial asthma].
2001 Aug
Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone.
2001 Aug
Lunelle monthly injectable contraceptive. An effective, safe, and convenient new birth control option.
2001 Aug
Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep.
2001 Dec
A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
2001 Dec
[Results of treatment based on endocrine therapy for bone metastasis from breast cancer].
2001 Dec
An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy.
2001 Dec
Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas.
2001 Dec
Hormone replacement therapy and endothelial function: the exception that proves the rule?
2001 Dec
Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women.
2001 Dec
Current options for injectable contraception in the United States.
2001 Dec
Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women.
2001 Dec
How to use progestin in hormone replacement therapy: an animal experiment.
2001 Feb
Monthly injection provides new contraceptive choice.
2001 Jan-Feb
Quinacrine non-surgical female sterilization in Bangladesh.
2001 Nov
A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys.
2001 Nov
Acute and mid-term combined hormone replacement therapy improves endothelial function in post-menopausal women with angina and angiographically normal coronary arteries.
2001 Nov
The influence of apo E phenotypes on the plasma triglycerides response to hormonal replacement therapy during the menopause.
2001 Nov 30
New options in contraception for adolescents.
2001 Oct
Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro.
2001 Oct
[Clinical analysis of pulmonary lymphangioleiomyomatosis].
2001 Oct 25
Are less than standard doses of hormone replacement therapy (HRT) effective for the treatment of hot flushes?
2001 Sep
Interactions between antiepileptic drugs and hormonal contraception.
2002
Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report.
2002 Apr
Contraceptive efficacy and patient acceptance of Lunelle.
2002 Aug
Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women.
2002 Aug
Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis.
2002 Aug
Effect of methyl testosterone administration on plasma viscosity in postmenopausal women.
2002 Aug
High-risk teen compliance with prescription contraception: an analysis of Ohio Medicaid claims.
2002 Feb
Effects of hormonal replacement therapy on oxidative stress and total antioxidant capacity in postmenopausal hemodialysis patients.
2002 Jan
Estrogen therapy for unstable angina: another bump for the bandwagon.
2002 Jan 16
[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
2002 Jul
Six months of hormone replacement therapy does not influence muscle strength in postmenopausal women.
2002 Jul 25
HRT: forever or never?
2002 Jul-Aug
Medroxyprogesterone-induced endocrine alterations after menopause.
2002 Jul-Aug
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study.
2002 Jun
New developments in contraception.
2002 Jun
Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women.
2002 Mar
Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women.
2002 Mar
Pharmacological characterization of the ATP-dependent low K(m) guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes.
2002 Mar 1
Effect of postmenopausal hormone therapy on cardiovascular risk.
2002 May
Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.
2002 May
Effect of medroxyprogesterone on pulmonary arterial pressure, exhaled nitric oxide, ECG and arterial blood gases.
2002 May
Contraceptive applications of estrogen.
2002 May-Jun
Influence of estradiol and gestagens on oxidative stress in the rat uterus.
2002 Sep
Chronic respiratory failure: an unusual cause and treatment.
2002 Sep
Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study.
2002 Sep 30
Patents

Patents

Sample Use Guides

Secondary Amenorrhea: PROVERA (medroxyprogesterone acetate ) tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days. Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of Organic Pathology: Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of PROVERA may be given daily for 5 to 10 days. Reduction of Endometrial Hyperplasia in Postmenopausal Women: Receiving Daily 0.625 mg Conjugated Estrogens
Route of Administration: Oral
Freshly isolated PBMCs (peripheral blood mononuclear cells) from normal blood donors were treated with physiologic MPA (medroxyprogesterone acetate) concentrations ranging from 0.003 to 5 ng/ml and infected with GFP-tagged R5-tropic or X4-tropic HIV-1 pseudoviruses by spinoculation. The infection was limited to a single cycle. Cells were stained with CD3, CD8 and CD14
Name Type Language
MEDROXYPROGESTERONE
HSDB   INN   MI   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
MEDROXYPROGESTERONE ACETATE SPECIFIED IMPURITY B [EP]
Common Name English
MEDROXYPROGESTERONE [VANDF]
Common Name English
MEDROXYPROGESTERONE ACETATE IMPURITY B [WHO-IP]
Common Name English
MEDROXYPROGESTERONE [WHO-IP]
Common Name English
NSC-27408
Code English
MEDROXYPROGESTERONE [WHO-DD]
Common Name English
MEDROXYPROGESTERONE [INN]
Common Name English
MEDROXYPROGESTERONE [MI]
Common Name English
17-HYDROXY-6.ALPHA.-METHYLPREGN-4-ENE-3,20-DIONE
Systematic Name English
MEDROXYPROGESTERONE ACETATE RELATED COMPOUND B [USP-RS]
Common Name English
G03AC06
Code English
MEDROXYPROGESTERONE [HSDB]
Common Name English
MEDROXYPROGESTERONE ACETATE RELATED COMPOUND B
USP-RS  
Common Name English
FARLUTAL INYECTABLE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C776
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
NDF-RT N0000175602
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-VATC QL02AB02
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-VATC QG03AC06
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-ATC G03DA02
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-VATC QG03FA12
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-VATC QG03DA02
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-ATC L02AB02
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-VATC QG03FB06
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-ATC G03AC06
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-VATC QG03AA08
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
NDF-RT N0000011301
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-ATC G03AA08
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-ATC G03FA12
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
LIVERTOX 590
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
WHO-ATC G03FB06
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C629
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
CAS
520-85-4
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
ChEMBL
CHEMBL717
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
DRUG CENTRAL
1659
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
INN
853
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
HSDB
3114
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
PUBCHEM
10631
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
EVMPD
SUB08699MIG
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
IUPHAR
2879
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
MESH
D008525
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
RXCUI
6691
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M7134
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1378023
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY USP-RS
FDA UNII
HSU1C9YRES
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
WIKIPEDIA
Medroxyprogesterone
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
ECHA (EC/EINECS)
208-298-6
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY
EPA CompTox
520-85-4
Created by admin on Sat Jun 26 13:15:48 UTC 2021 , Edited by admin on Sat Jun 26 13:15:48 UTC 2021
PRIMARY